FDA warns The HCG Institute over misleading claims for compounded semaglutide sold online.
What happened
In August 2025, FDA reviewed the website thehcginstitute.com and found it offered compounded drug products, including semaglutide. FDA said the site’s claims were false or misleading—for example, calling compounded semaglutide “clinically proven” and “FDA-inspected” and saying it is the same as FDA-approved semaglutide. Compounded drugs are not FDA-approved, so FDA said the products are misbranded.
What FDA found
FDA said the website’s claims about compounded semaglutide are false or misleading, making the drug misbranded.
FDCA section 502(a) [21 U.S.C. § 352(a)]FDA said advertising or promotion of a compounded drug that is false or misleading makes it misbranded.
FDCA section 502(bb) [21 U.S.C. § 352(bb)]FDA said the site implied compounded semaglutide is the same as an FDA-approved product when compounded drugs are not FDA-approved.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]FDA said introducing or delivering these misbranded drugs into interstate commerce is prohibited.
FDCA section 301(a) [21 U.S.C. § 331(a)]FDA said receiving or delivering misbranded drugs in interstate commerce is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
Within 15 working days, FDA tells the company to send a written response to CDER’s Office of Compounding Quality and Compliance describing steps taken to fix the violations, prevent recurrence, and include supporting documents; if it disagrees, it must explain why.
Who should pay attention
- telehealth and online sellers of compounded GLP-1 drugs
- compounding pharmacies and their marketing partners
- websites making drug efficacy or FDA-approval claims
This is a summary. Read the original letter on fda.gov.